<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01871077</url>
  </required_header>
  <id_info>
    <org_study_id>SOPH156-0612/I</org_study_id>
    <nct_id>NCT01871077</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of the Ophthalmic Solution PRO-156 in Ophthalmologically Healthy Volunteers.</brief_title>
  <official_title>Phase I Clinical Trial to Assess the Safety and Tolerability of the Ophthalmic Solution PRO-156 Over the Ocular Surface of Ophthalmologically Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerability of the ophthalmic solution
      PRO-156 over the ocular surface of ophthalmologically healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I, open label and unicentric clinical trial to evaluate the safety and tolerability
      of the ophthalmic solution PRO-143 over the ocular surface of ophthalmologically healthy
      volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of PRO-156 ohthalmic solution</measure>
    <time_frame>11 days</time_frame>
    <description>Evaluate safety of PRO-156 in the ocular surface by the prescence of ocular signs and symptoms,visual acuity (VA), intraocular pressure (IOP), corneal and conjunctival staining (Fluoroscein and lissamine green staining).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of PRO-156 Ophthalmic Solution</measure>
    <time_frame>11 days</time_frame>
    <description>Evaluation of ocular symptoms (redness, burning, foreign body sensation, itching, eye discharge and tearing)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PRO-156</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-156</intervention_name>
    <description>Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.</description>
    <arm_group_label>PRO-156</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female.

          -  Age between 18 and 40 years old at screening visit.

          -  Signed informed consent

        Exclusion Criteria:

          -  Patient with one blind eye.

          -  Any ocular or systemic condition.

          -  Visual acuity of 20/100 in any eye.

          -  Use of ocular or systemics medications.

          -  Contraindications or sensitivity to any component of the study treatment.

          -  Contact lens users.

          -  Ocular surgery within the past 3 months..

          -  Pregnant, nursing or childbearing potential women who were not using effective
             contraception.

          -  Participation in any studies of investigational drugs within 90 days previous to the
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Casillas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Independent Clinical Research Center</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 23, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

